CME Movie Night: Cured

Friday, 6:00 PM

This documentary highlights a previously underappreciated activist campaign in the struggle to achieve normality for the LGBTQ community. For years, the APA’s DSM listed homosexuality as a mental illness. In 1973, the APA’s Board of Trustees finally voted to remove homosexuality from the DSM. All those “suffering” from homosexuality were thereby “cured”—hence the title of this important film. Five years in the making, Cured sheds new light on a pivotal victory, while situating the APA story within the larger context of the modern movement for LGBTQ equality. Since its release, Cured has attracted nearly two million viewers from across the globe.

Post-screening discussion moderated by Omair Abbasi, MD, FAPA and Ludmila De Faria, MD, DFAPA

Andres J. Pumariega, MD, DLFAPA

Behavioral Health Collaborative Care: Florida Pediatric Experience ( 1.0 CME)

Saturday, 8:00 AM

Dr. Pumariega’s career has focused on children’s mental health systems of care and underserved populations. He is Professor and Chief, Division of Child and Adolescent Psychiatry, University of Florida. He has headed four divisions of Child & Adolescent Psychiatry, three psychiatry departments, and many statewide service system programs and national committees/ organizations. He has lectured/ written extensively (over 250 publications, 250 abstracts, and 6 textbooks). He is a Distinguished Life Fellow of the APA and AACAP, Fellow of the American College of Psychiatrists, American Orthopsychiatry Association, and World Social Psychiatry Association. His awards include Alumni Hall of Fame of the University of Miami Miller School of Medicine (1999), AACAP’s APA’s Simon Bolivar Award for Hispanic Psychiatry (2003), Jeanne Spurlock Award on Diversity/Culture (2007), and APA’s Agnes Purcell McGavin Award for Career Achievement in Child Psychiatry (2024).

Donna Sudak, MD, DLFAPA

Empowering Psychiatrists with Effective Psychotherapy Training (1.5 CME)

Saturday, 9:00 AM

Donna Sudak, MD, is Professor, Senior Associate Training Director and Director of Psychotherapy Training in the Department of Psychiatry at the Drexel University College of Medicine. She is a clinician-educator with a wealth of experience and multiple awards for her teaching. She has made a number of significant contributions to the literature in CBT education and has played a major role in developing suggested curricula and guidelines for resident competency in Cognitive Behavior Therapy. Dr. Sudak has multiple publications regarding combining treatment with medication and CBT. In addition to her teaching responsibilities at Drexel University College of Medicine, Dr. Sudak is an adjunct faculty member at the Beck Institute.

Mark Gold, MD, DFASAM, DLFAPA

My Career in Translational Addiction Research – the First 50 Years of Discovery & Publications (1.5 CME)

Saturday, 11:00 AM

Mark S. Gold, MD, DFASAM, DLFAPA, is a world-renowned expert on addiction-related diseases and has worked for 40+ years developing models for understanding the effects of opioid, tobacco, cocaine, and other drugs, as well as food, on the brain and behavior. Dr. Gold is a former professor in the Department of Neuroscience, distinguished professor, and chairman of the Department of Psychiatry at the University of Florida College of Medicine, where he founded the Division of Addiction Medicine. His translational research has led to an understanding of the role of the nucleus locus coeruleus in addiction, the discovery of clonidine’s efficacy in opiate withdrawal, and the dopamine depletion hypothesis in understanding cocaine addiction.

Stephen E. Nadeau, MD

The Neuroscience of Apathy & Abulia  (1.5 CME)
Saturday, 1:30 PM

Stephen Nadeau, MD, is a graduate of MIT and the University of Florida College of Medicine. He has published broadly in the fields of cognitive and behavioral neurology, cognitive neuroscience, computational neuroscience, neurorehabilitation, and the opioid crises. He has conducted many small randomized controlled trials and been on the leadership teams of two Phase III trials. His clinical practice has centered on patients with cognitive impairment of many etiologies, including Alzheimer’s disease.

Wendy Oliver-Pyatt, MD, FAPA

Breakthroughs in Treatment: Past, Present and Future of Eating Disorders  (1.5 CME)

Saturday, 3:45 PM

Dr. Wendy Oliver-Pyatt is a world-leading expert on treating eating disorders and complex mental health presentations. With more than 25 years of clinical experience, she has developed six distinctive treatment programs, all grounded on a strong bio-psycho-social foundation, and incorporating intensive psychotherapy, with behavioral foundations, and high medical standards. Wendy has developed a unique treatment approach that delves into the underlying issues that place a person at risk for mental health conditions and eating disorders and lead to healing, health and inner peace.

Dr. Oliver-Pyatt received her specialty training at New York University-Bellevue Hospital in New York City, she has also held faculty positions at New York University, Albert Einstein School of Medicine and University of Nevada School of Medicine. Wendy is Board Certified by the American Board of Psychiatry and Neurology and in both Adult and Addiction Psychiatry. She is the author of two books, most recently Questions and Answers on Binge Eating Disorder, A Guide for Clinicians. She is a Fellow of the Academy for Eating Disorders and the International Association of Eating Disorder Professionals. She has received Senatorial Recognition for her commitment to the mental health treatment community.

Sanjali Kumar, MD

Magnetizing Minds: An In-Depth Discussion on TMS  (1.5 CME)

Sunday 8:00 AM

Dr. Sanjali Kumar, MD, is an psychiatrist and Instructor in Psychiatry at Harvard Medical School. She received her medical degree from Creighton University School of Medicine and completed residency at Brigham and Women's Hospital/Harvard Medical School. Dr. Kumar is a part of the new TMS (Transcranial Magnetic Stimulation) treatment center at McLean Hospital, where she also works in the Transcranial Magnetic Stimulation Research Program within the Division of Depression and Anxiety Disorders. Her work aims to enhance the effectiveness of TMS for treating brain disorders, contributing significantly to advancements in this field.

Jacob M. Appel, MD, JD, MPH, HEC-C, DFAPA

Rethinking Capacity: Toward a Values-Prioritizing Approach  (1.5 CME)

Sunday 10:15 AM

Jacob M. Appel is currently Professor of Psychiatry and Medical Education at the Icahn School of Medicine at Mount Sinai in New York City, where he is Director of Ethics Education in Psychiatry, Associate Director of the Academy for Medicine and the Humanities, and Medical Director of the Mental Health Clinic at the East Harlem Health Outreach Program. Jacob is the author of five literary novels, eleven short story collections, an essay collection, a cozy mystery, a thriller, two volumes of poems and a compendium of dilemmas in medical ethics. He is co-chair of the Group for the Advancement of Psychiatry’s Committee on Psychiatry & Law and a Councilor of the New York County Psychiatric Society and of the American Academy of Psychiatry & Law.

Jose M. Rubio, MD, PhD

From Inertia to Action: Integrating Muscarinic Therapies into Schizophrenia Practice (1.0 CME)

Sunday 12:00 PM

Jose M. Rubio, MD, PhD, is Assistant Professor of Psychiatry at the Feinstein Institutes for Medical Research and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He is a board-certified psychiatrist and physician-investigator. Dr. Rubio obtained his MD and PhD from the Universitat de Valencia and Universidad Complutense de Madrid (Spain) respectively, and psychiatry residency at the Zucker Hillside Hospital – Hofstra University (New York). After completing residency in 2017, he obtained a Career Development Award by the National Institutes of Health to study biomarker development and relapse in schizophrenia.

As an early career investigator, Dr. Rubio has published over 50 articles, focusing on the application of evidence-based interventions in the real world, neuroimaging biomarkers, and prevention of relapse in schizophrenia. Some of the phenomena that he studies is the underutilization of long acting injectable antipsychotics and clozapine, and the neurobiological mechanisms leading to relapse or decrement in antipsychotic efficacy over time.

Dr Rubio regularly lectures on the treatment of schizophrenia in a variety of academic and industry settings. In addition, he supervises residents in a specialized psychosis clinic and co-leads the research track at the Zucker Hillside Hospital psychiatry residency program. Dr. Rubio has received various awards, including the early career investigator travel award for the Schizophrenia International Research Society (SIRS) and the American College of Neuropsychopharmacology (ACNP) and the Alkermes Pathways Award for Junior Investigators.